Prothena
Presence
Prothena is one of the...
Prothena is a company listed under the stock ticker PRTA (US).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Prothena
- Gene Kinney, President, Chief Executive Officer and Director
- Oleg Nodelman, Director
- Billy Dunn, Director
Popular executive movements at Prothena
- David Ford has joined the company as Chief People Officer (posted on March 5 2024).
- Daniel Welch who is Director, will be promoted to Chairman of the Board in Aug. 2024 (posted on February 22 2024).
- Lars Ekman, Chairman of the Board, will leave the company in Aug. 2024 (posted on February 22 2024).
Create your alert
to follow the executive moves at Prothena.
Biotechnology
Prothena has 2,276 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
Popular contacts in Biotechnology
News
Press releases by Prothena
- Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease | Prothena Corporation plc
- RSS NEWS FEEDS | Prothena Corporation plc
- Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Prothena Corporation plc
- Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress | Prothena Corporation plc
- Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study | Prothena Corporation plc
- Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15 | Prothena Corporation plc
- Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders | Prothena Corporation plc
- Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Prothena Corporation plc
- Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update | Prothena Corporation plc
- Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders | Prothena Corporation plc
- View more press releases Close
Social media about Prothena
- Prothena on Wikipedia, Google News & Yahoo Finance
- Prothena on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Gene Kinney 
